1800 244 735

Understanding expansions at the single cell level

In two recent studies, researchers looked at how different parts of the brain are affected by CAG expansions in Huntington’s disease (HD) at the level of individual brain cells. The scientists looked at post-mortem brains from people with and without HD to track molecular changes in different brain regions called the cortex and striatum. These studies have provided new insights into what contributes to HD. Let’s get into it!

Specific brain areas are prone to damage in HD

For a long time now, we have known that some areas of the brain are affected more than others in people with HD. Specific types of brain cells in these vulnerable parts of the brain tend to die off more quickly than others, in a process known as degeneration.

However, the underlying reasons for why some cells are affected more than others are not very clear. Lots of researchers from around the world have been trying to figure this out, as it might shine a light on exactly how HD progresses and give us clues as to how we might treat it.

In two recent papers coming from the same laboratory at Rockefeller University in New York, scientists have looked very closely at molecular changes which happen in different types of brain cells in HD. Using generously donated post-mortem brain samples from people with or without HD, the team carefully separated the brain tissue into individual cells.

The two studies focused on different parts of the brain; the first concentrating on a region called the cortex, and the second looking into cells which make up the striatum and cerebellum. Each brain region is made up of lots of different types of cells so they used special markers to sort all the cells and work out which cells were which type. They were then able to measure all sorts of molecular changes from the different types of cells using cutting-edge genetics technologies.

Linking somatic expansion to when symptom start

One of the changes the scientists looked at in each cell was the CAG number in the huntingtin gene. HD is defined at the genetics level as people who have more than 36 repeating C-A-G DNA letters in their huntingtin gene, with most folks with HD having 40-50 CAGs compared to people without HD who have somewhere around 18 CAGs.

For some time now we have known that in certain types of cells this CAG number is not stable and will change over the course of someone’s lifetime, often getting much longer. This process of CAG increases in some cells is known as somatic expansion. It’s important to note that blood cells happen to be a cell type with stable CAG repeat numbers compared to other cell types. So if you received a genetic test when you were 18, that number will almost surely be the same if you were to get tested again at age 50.

Somatic expansion became a hot topic in HD research when studies of genetic modifiers, traits which change the age of symptom onset, pointed to the exact genes which we think control somatic expansion. Together, this suggests there is a link between how big a CAG number gets during the lifetime of someone with HD and how early they will experience symptoms of the disease.

Thanks to tremendous advances in DNA sequencing technology, we can now look at how long the CAG number is in each individual cell. In fact, this is exactly what the team from Rockefeller did. So what did they find?

Cool conclusions from the cortex

In the first study published at the start of this year, the scientists zoomed into a part of the brain called the cortex – the outer part of the brain with all the wrinkles. Studies which have done detailed brain scans of people with HD have shown a thinning of this part of the brain. They’ve also found that connections between brain cells are lost in this part of the brain over the course of the disease and that the cells tend to die early on. Changes in the cortex cause cognitive decline and psychiatric symptoms that many people with HD experience.

The scientists found that a specific type of brain cell, called Layer 5a corticostriatal projection neurons (phew, what a mouthful!), is lost in people with HD. These cells die early during the disease, in both humans and monkeys. While these cells are found in the wrinkly cortex, they connect all the way to the centre of the brain, to the striatum, the region that’s most vulnerable in HD.

Interestingly, the team found that increases in the CAG number happen in many different types of nerve cells in the cortex, including those that remain relatively healthy. CAG increases were seen in the vulnerable Layer 5a brain cells but also in other cells called Betz cells, which aren’t so badly affected by HD. This pointed the researchers to the conclusion that having an increase in CAG number is not enough on its own to cause cells to get sick.

Study surprises from the striatum

In the second study, the researchers focused on the striatum, a brain region in the very center of our heads and the part of the brain most affected by HD. A type of brain cell, called medium spiny neurons or MSNs, are found in this part of the brain and are known by researchers to be the most vulnerable to death in folks with HD.

When the team looked at the CAG number in individual cell types from this part of the brain, they found that the MSNs had the biggest increase in their CAG number. However, other cells in the striatum which are not so affected in HD, such as a type of nerve cell called ChAT+, also had big changes in their CAG number.

The researchers looked at cells from the brain of someone with a similar brain disease to HD called SCA3 (spinocerebellar ataxia type 3), which is caused by an increase in CAGs in a gene called Ataxin3. Folks with SCA3 suffer loss of brain cells but this is not specific to the MSN cell type like it is in HD.

In this disease, they also found that the CAG number increased in the MSN cells, but not other types of brain cells, even though the MSN cells in these folks’ brains weren’t so affected. This means that MSNs may just be particularly prone to expanding CAG repeats, regardless of what gene has the long CAG repeats. However the ever expanding CAG repeat may not be the direct reason that those cells die.

So what does this all mean?

What both of these studies point to is the idea that increasing CAG number in HD could be just one of the necessary steps towards cells getting sick. On its own, somatic expansion might be insufficient to cause that cell to die, as the researchers report CAG expansions in cells not vulnerable to death in HD, like the Betz cells.

Both studies also looked at other features of these cells. They did a deep dive into the genes that are turned on or off in every cell in brains of people with and without HD. What they found is that HD causes global changes in the types of genes that are on or off. This has also been shown by many other researcher groups before. Researchers think that these changes may cause toxicity, affecting the health of the cells, eventually contributing to their death.

The researchers think that connection issues could also be contributing to cell death. In the cortex, they found alterations in vulnerable cells that change the way they can connect and communicate with cells in other areas of the brain. This disconnection not only reduces the ability of one brain area to communicate with another, but it also weakens the cells themselves over time.

Other research groups are still testing the hypothesis that somatic expansion is the major driver of HD. Different scientists are using different technologies to measure the CAG numbers and early previews of these datasets at the recent therapeutics meeting suggest that this can lead to different results. We expect to see a lot more work in this space in the future.

Science only made possible by patient families

It is really important to note that nearly all of the findings of these two very important studies were made possible by the researchers having access to extremely precious post-mortem brain samples. In both studies, the scientists compared brain material from people either with or without HD, who had passed, who generously donated their brains to science to further research. This is an amazing selfless act that has tremendous impacts for research to better understand HD, with the ultimate aim of one day finding a drug to slow, stop, or reverse the disease.

Whilst brain donation is not something that everyone might be comfortable or able to do, if this is something you are interested in doing, the HDSA, HSC, the Brain Donor Project, and other patient organisations, have information and resources about what this decision involves and next steps.

Latest Research Articles

Blue skies for Skyhawk: Positive news from Phase 1 trial for SKY-0515

Published date: 11 July, 2024

The stormy trial updates that hung over the Huntington’s disease (HD) field in 2021 have certainly parted, making way for the bright and clear forecast we’ve had so far in 2024! Close on the heels of recent positive trial news from Sage Therapeutics, PTC Therapeutics, Wave Life Sciences, and uniQure, we’ve received more encouraging results ... Read more

Buckle in: Gene therapy AMT-130 appears to slow down signs of Huntington’s disease in Phase I/II clinical trial

Published date: 10 July, 2024

New data from uniQure, who developed a one-and-done gene therapy for Huntington’s disease (HD) called AMT-130, indicates that the drug is relatively safe and might be able to slow down signs and symptoms of HD. AMT-130 is currently under investigation in Phase I/II clinical trials in Europe and the US which are mainly focused on ... Read more

Positive news from Wave Life Sciences SELECT-HD trial

Published date: 28 June, 2024

On 25th June 2024, Wave Life Sciences shared the results of their SELECT-HD clinical trial. This trial tested a therapy called WVE-003, designed to only lower the expanded, harmful form of the huntingtin (HTT) protein found in people with Huntington’s disease (HD). The data released today give positive updates on the safety of this therapy ... Read more

No pivot needed for PTC-518

Published date: 21 June, 2024

On June 20, 2024, we received an update from PTC Therapeutics about their ongoing trial, PIVOT-HD. PIVOT is testing PTC-518, a small molecule drug, taken as a pill, that lowers huntingtin (HTT) in people with Huntington’s disease (HD). Their most recent update shared data from people who had been on the drug for 12 months. ... Read more

SURVEYOR opens the door for drugs that treat cognition

Published date: 12 June, 2024

Sage Therapeutics released a press statement on June 11th that focuses on the main results of a study called SURVEYOR, aimed at studying cognition (thinking) in Huntinton’s disease (HD) and testing the safety of a drug called dalzanemdor (previously SAGE-718). Let’s talk about what we know and what’s next! Amplifying nerve cell messages to improve ... Read more

The VIP section: velvet ropes for the brain and how to get in

Published date: 10 June, 2024

Two separate research groups recently published work on the blood-brain barrier (BBB). You can think of the BBB like a bouncer that keeps the riffraff out of the VIP section that is your brain. One group advanced how the brain’s barrier is modeled in the lab using stem cells. Another group developed a harmless virus ... Read more